OS update LAURA

In this video, Prof Suresh Ramalingam, Medical Oncologist at the  Emory School of Medicine in Atlanta (GA, USA) discusses the updated overall survival (OS) results of the randomized, phase III LAURA study which were presented as a late breaking abstract during ELCC 2025.

Previously, the LAURA study demonstrated an impressive benefit in progression-free survival (PFS) for patients with unresectable, stage III, EGFR-mutant non-small cell lung cancer (NSCLC) who received osimertinib vs. placebo after chemoradiotherapy (CRT) (HR[95%CI]: 0.16[0.10-0.24]; p< 0.001). During ELCC 2025, the second interim analysis for OS was presented with 31% of data maturity.

With a median OS of 58.8 months for osimertinib and 54.0 months for placebo, this updated analysis confirms and reinforces the trend for a better OS in patients receiving maintenance therapy with osimertinib. However, at this timepoint, the benefit in OS did not yet reach statistical significance (HR[95%CI]: 0.67[0.40;1.14]; p= 0.140). At 48 months, 70% of patients in the osimertinib arm were still alive as compared to 52% in the control arm. 

Importantly, about 90% of patients in the placebo arm received a third generation TKI at the time of disease progression (mainly osimertinib). This trial therefore effectively compares upfront osimertinib after CRT to deferred osimertinib once the patient suffers a disease recurrence. The significant benefit in PFS together with the strong trend for a better OS convincingly supports the argument that upfront osimertinib maintenance is likely the better choice in this setting.